The direct selling industry in India has emerged as a legally recognised and rapidly expanding sector, regulated primarily under the Consumer Protection (Direct Selling) Rules, 2021, along with the 2023 amendments issued under the Consumer Protection Act, 2019. The regulatory environment has continued to evolve in recent years. Amendments introduced in 2023 clarified the legal definition of direct selling, while the 2025 reforms to consumer protection enforcement established mandatory online grievance mechanisms and imposed a 90-day timeline for dispute resolution. In addition, a July 2024 notification issued by the Food Safety and Standards Authority of India (FSSAI) introduced a specialised compliance category for direct sellers dealing in food and wellness products. This memorandum outlines the current legal framework, compliance obligations, prohibited activities, and regulatory considerations relevant to entities operating in the Indian direct selling sector. Historical and Legislative Context Before 2021, India did not have a dedicated legal framework governing direct selling. As a result, businesses in the sector often faced scrutiny under the Prize Chits and Money Circulation Scheme (Banning) Act, 1978. Formal statutory recognition of “direct selling” was introduced through Section 2(13) of the Consumer Protection Act, 2019, which defines the activity as the marketing, distribution, and sale of goods or services through a network of sellers rather than permanent retail outlets. Subsequent amendments and regulatory notifications have refined this framework over time. Current Legal Framework (as of 3 May 2026) The regulatory structure applicable to direct selling in India is multi-dimensional and involves several interrelated statutes and regulations: Consumer Protection (Direct Selling) Rules, 2021 (as amended in 2023): These rules establish the primary compliance framework, define key concepts, and prescribe obligations for direct selling entities (DSEs) and direct sellers. Consumer Protection Act, 2019 (including 2025 reforms): Provides broader consumer rights protections, including online complaint filing, stricter accountability standards, and accelerated adjudication timelines. Companies Act, 2013 and LLP Act, 2008: Require DSEs to be duly incorporated prior to commencing operations in India. Income Tax and GST Laws: Mandate PAN, TAN, and GST registration along with maintenance and filing of tax records. Food Safety and Standards Act, 2006: Requires food and nutraceutical direct sellers to register under the dedicated “Direct Seller” category introduced in FoSCoS during 2024. Foreign Exchange Management Act, 1999 and FDI Policy: Govern foreign investment structures and compliance obligations applicable to overseas direct selling entities operating in India. Prize Chits and Money Circulation Scheme (Banning) Act, 1978: Continues to prohibit fraudulent money circulation and pyramid schemes. Registration and Structural Compliance Any DSE intending to operate in India must complete several pre-operational formalities, including: Registration with the Department for Promotion of Industry and Internal Trade (DPIIT). Incorporation as a company, partnership firm, or LLP. Establishment of a registered office within India. Procurement of PAN, TAN, and GSTIN registrations. Acquisition of sector-specific licences, including FSSAI or CDSCO approvals where applicable. Maintenance of a functional website containing details of products, pricing, grievance mechanisms, and contact information. Entities are also required to maintain statutory and financial records at their registered office, including incorporation documents, tax filings, audited financial statements, and records of direct sellers and customer transactions. Mandatory Compliance Officers The Rules require DSEs to appoint designated officers, including: A Chief Compliance Officer, responsible for legal and regulatory compliance; A Nodal Contact Person, who must be an Indian resident available for coordination with law enforcement authorities; and A Grievance Officer, responsible for acknowledging complaints within 48 hours and resolving them within one month. Duties and Obligations of Direct Selling Entities DSEs are subject to extensive operational and consumer protection obligations. These include: Maintaining transparent and regularly updated online disclosures; Executing written agreements with direct sellers; Monitoring the conduct of network participants; Ensuring consumer data remains stored within India; and Prohibiting entry fees or registration charges for participation in the business model. Consumer protection duties include timely delivery of goods, mandatory acceptance of returns for defective products, and transparent disclosure of cancellation and refund rights. Under the 2025 reforms, complaints filed through the government’s centralised online portal must be acknowledged within 48 hours and resolved within 30 days. Restrictions and Prohibited Practices The regulatory framework imposes strict prohibitions on activities commonly associated with unlawful schemes. These include: Pyramid structures where compensation is driven primarily by recruitment rather than product sales; Money circulation schemes prohibited under the 1978 Act; Charging joining or subscription fees; Misleading or deceptive marketing practices; and Unverified health or medical claims relating to products. Direct sellers are additionally prohibited from visiting consumers without prior appointments or identity verification and may not distribute unauthorised promotional material. Consumer Rights and Cooling-Off Period Consumers are entitled to receive complete product and compensation plan disclosures before enrolment or purchase. They also possess rights relating to refunds, complaint resolution, and data privacy. Although the Rules do not prescribe a mandatory cooling-off period, industry practice generally recommends a minimum period of 30 days for cancellation without penalty. Applicability to Foreign Direct Selling Entities The Direct Selling Rules apply not only to Indian entities but also to foreign-incorporated businesses offering goods or services to consumers in India. Overseas DSEs must therefore: Maintain a registered office in India; Appoint resident compliance officers; Ensure Indian consumer data remains within India; and Structure investments in compliance with FEMA and FDI regulations. The RBI’s expanded 2025 interpretation of “control” has increased scrutiny of layered ownership structures and indirect foreign influence arrangements. Regulatory and Industry Bodies Key authorities and industry organisations relevant to the sector include: The Ministry of Consumer Affairs; DPIIT; The Indian Direct Selling Association (IDSA); The Federation of Indian Direct Selling Industries (FIDSI); FSSAI; and State-level regulatory authorities. Industry Overview India’s direct selling market has experienced substantial growth in recent years. By 2025, the sector accounted for approximately 5.7% of global direct selling revenue, with health and wellness products contributing the largest share of industry earnings. Cosmetics and personal care products represent the fastest-growing segment, while the industry continues to generate large-scale employment and entrepreneurial opportunities, particularly for women. Emerging Regulatory Trends Several developments are expected

In the modern age of medical advancements, biobanks have emerged as invaluable repositories of genetic information, fuelling groundbreaking research and personalized medicine. However, as genetic data becomes more accessible, concerns over privacy and ethical safeguards grow increasingly pressing. Biobanks store biological samples—such as blood, tissue, and DNA—and relatedhealth data, allowing researchers to study genetic markers, disease progression, and potential treatments. From national biorepositories to specialized research initiatives, these genetic databases promise revolutionary insights into human health. Yet, for all their benefits, biobanks pose significant risks to personal privacy. Genetic information is deeply personal, uniquely identifying individuals in ways fingerprints cannot. While anonymization techniques exist, they are not foolproof, leaving sensitive data vulnerable to breaches or unauthorized access. India’s Digital Personal Data Protection Act (DPDPA), 2023 marks a significant step in data privacy, but how does it compare to global genetic privacy laws? While frameworks like the EU’s GDPR and U.S. GINA explicitly address genetic data, India’s approach remains broader, leaving room for interpretation. GDPR (Europe): Defines genetic data as sensitive personal information, requiring explicit consent for collection and processing. GINA (U.S.): Focuses on preventing genetic discrimination in employment and health insurance DPDPA (India): Does not explicitly classify genetic data as sensitive, relying on general personal data protections. India’s DPDPA Section 17(2)(b) allows data processing for research without stringent safeguards, unlike GDPR’s strict ethical oversight. This raises concerns about genetic profiling and potential misuse. While India’s DPDPA is a step forward, its lack of explicit genetic data protections makes it weaker than GDPR and GINA. As genetic research expands, India may need dedicated genetic privacy laws to prevent misuse and ensure ethical data handling

Healthcare is one of the most highly regulated industries in the world, and for good reason—human lives are at stake. However, as medical technology advances and patient expectations evolve, the legal challenges surrounding healthcare are becoming more complex than ever. From patient rights to telemedicine and data privacy, today’s healthcare providers must navigate a legal minefield to stay compliant and protect their patients. 1. The Patient’s Right to Know: Informed Consent in the Digital Age Gone are the days when a simple signature was enough to establish informed consent. Today, with artificial intelligence assisting diagnoses and experimental treatments gaining traction, patients need more transparency than ever. Laws governing informed consent require that healthcare providers thoroughly explain risks, alternatives, and expected outcomes. But what happens when AI plays a role in medical decisions? Can a machine be held liable for a misdiagnosis? Courts are just beginning to tackle these questions, making this a rapidly evolving legal issue. 2. Telemedicine: Convenient but Legally Complicated Telemedicine has revolutionized healthcare by making medical consultations more accessible, especially in remote areas. However, it comes with a host of legal concerns, including: Licensing Issues: A doctor licensed in one state or country may not be permitted to practice in another via telehealth. Data Security Risks: Virtual consultations mean sensitive patient data is being transmitted online, increasing the risk of cyberattacks. Malpractice Concerns: How do courts determine liability if a misdiagnosis occurs over a virtual consultation? Despite these hurdles, regulatory bodies are working to create frameworks that balance accessibility with legal protection. 3. Healthcare Data Privacy: Are We Really in Control? The rise of electronic health records (EHRs) and wearable health tech means patient data is more vulnerable than ever. Laws like HIPAA in the U.S. and GDPR in Europe place strict controls on how healthcare providers handle sensitive medical information. But with data breaches becoming more frequent, it begs the question—are these laws enough? Should hospitals be held more accountable for cyberattacks, or should tech companies bear some of the responsibility? 4. Medical Malpractice: The High Cost of Errors Medical errors are a leading cause of death worldwide. While malpractice lawsuits exist to hold healthcare providers accountable, they also drive up the cost of medical care due to rising insurance premiums. Some legal systems have introduced alternative dispute resolution mechanisms, such as medical tribunals, to reduce frivolous lawsuits while ensuring legitimate claims are addressed fairly. 5. The Future of Healthcare Law: What’s Next? With advancements in biotechnology, gene editing, and AI-driven diagnostics, the future of healthcare law will continue to evolve. Key areas to watch include: Regulation of AI in Medicine – Should AI be classified as a medical practitioner when making diagnostic decisions? Ethical Boundaries in Genetic Editing – Should there be stricter global laws governing gene therapy and human DNA modification? Cross-Border Healthcare Access – Will we see more international collaboration on medical licensing and patient rights? Conclusion The intersection of healthcare and law is more critical than ever, affecting patients, doctors, hospitals, and policymakers alike. As medical technology advances, so too must the legal frameworks that govern it. Staying informed about these evolving legal challenges isn’t just important—it’s essential for the future of safe, ethical, and effective healthcare. Disclaimer: The information provided in this article is for general informational purposes only and does not constitute legal or medical advice. While every effort has been made to ensure accuracy, laws and regulations may vary by jurisdiction and are subject to change. Readers should consult a qualified legal professional for specific legal guidance related to healthcare laws and compliance. The author and publisher disclaim any liability for decisions made based on the information provided in this article.